SCHEDULE: Adage Capital Management Discloses Inovio Stake

Adage Capital Management, L.P. has reported a beneficial ownership of 5.84% in Inovio Pharmaceuticals, Inc., including shares issuable upon warrant exercise.

Summary

• Adage Capital Management, L.P. (ACM), through its investment vehicle Adage Capital Partners, L.P. (ACP), has filed a Schedule 13G, indicating beneficial ownership of 4,233,529 shares of Inovio Pharmaceuticals, Inc. common stock.
• This holding represents 5.84% of the company's outstanding common stock as of March 12, 2026.
• The reported shares include 3,428,571 shares of common stock issuable upon the exercise of warrants held by ACP.
• Robert Atchinson and Phillip Gross, as managing members of entities related to ACM and ACP, are also listed as reporting persons.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a significant stake is disclosed, it's a passive investment report (Schedule 13G) and does not contain operational updates or financial performance metrics from Inovio itself.

Positives

• Adage Capital Management has taken a significant stake, indicating confidence in Inovio Pharmaceuticals.
• The beneficial ownership of 5.84% suggests a notable investment position.
• Inclusion of shares issuable upon warrant exercise indicates a potential for increased ownership and strategic interest.

Negatives

• The filing is a Schedule 13G, which typically indicates passive investment rather than an attempt to gain control, suggesting no immediate activist intent.
• The reporting persons disclaim beneficial ownership beyond their pecuniary interest, which is standard for investment managers but can sometimes obscure true control.

Risks

• The primary risk for investors is the inherent volatility and uncertainty associated with pharmaceutical and biotechnology companies, particularly those with ongoing clinical development.
• The reliance on warrant exercises for a significant portion of the reported shares introduces a risk if those warrants are not exercised or if the underlying stock price does not support exercise.
• The filing does not detail specific business risks of Inovio Pharmaceuticals, but general market and industry risks apply.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Inovio Pharmaceuticals, Inc. It is a disclosure of beneficial ownership by Adage Capital Management.

Management Comments

• The filing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Adage Capital Management indicates a significant passive investment in Inovio Pharmaceuticals. Such filings often precede or coincide with shifts in institutional investor sentiment within the biotechnology sector, which is characterized by high R&D costs and regulatory hurdles.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a known investment manager like Adage Capital Management could be interpreted positively by the market, potentially influencing investor sentiment and share price.
• Creditors: No direct impact mentioned.
• Employees: No direct impact mentioned.
• Suppliers/Customers: No direct impact mentioned.

Next Steps

• Monitor future filings from Adage Capital Management for any changes in their stake in Inovio Pharmaceuticals.
• Observe Inovio Pharmaceuticals' own SEC filings for operational and financial updates that might influence the value of Adage's investment.

Key Dates

Recommendation

This filing is a disclosure of passive beneficial ownership by an investment manager and does not contain operational or financial performance data for Inovio Pharmaceuticals. Therefore, it does not provide sufficient information to make a buy or sell recommendation. A 'hold' recommendation is appropriate, pending further company-specific news or financial reports.

Keywords

Inovio Pharmaceuticals, Schedule 13G, Adage Capital Management, beneficial ownership, warrants, common stock, investment, SEC filing